Research Article
Additive Value of Biomarkers and Echocardiography to Stratify the Risk of Death in Heart Failure Patients with Reduced Ejection Fraction
Table 1
Clinical features of the study cohort.
| Variable | All patients () |
| Age (years) | 59 ± 12 | Male gender, (%) | 357 (83) | Body mass index (kg/m2) | 27 ± 4.5 | Etiology, (%) | | Ischemic | 164 (38) | Nonischemic | 267 (62) | Comorbidities, (%) | | Hypertension | 120 (28) | Diabetes | 81 (19) | COPD | 40 (9) | New York Heart Association class, (%) | | I | 89 (21) | II | 265 (61) | III-IV | 77 (18) | Systolic blood pressure (mmHg) | 115 ± 18 | Heart rate (beats/minutes) | 68 ± 12 | Rhythm, (%) | | Sinus | 329 (77) | Atrial fibrillation/flutter | 35 (8) | Pacemaker | 66 (15) | Glomerular filtration rate, MDRD (ml/min per 1.73 m2) | 64 ± 17 | Hgb (mg/dl) | 13.9 ± 1.7 | BUN (mg/dl) | 46 ± 19 | Medications, (%) | | ACE-inhibitors/ARB | 340 (77) | Beta-blockers | 403 (93) | Aldosterone antagonist | 246 (57) | Ivabradine | 11 (3) | Digoxin | 52 (12) | Furosemide (mg) | 74 ± 100 | ICD, (%) | 236 (55) | CRT, (%) | 98 (23) |
|
|
COPD: chronic obstructive pulmonary disease; Hgb: hemoglobin; BUN: blood urea nitrogen; ICD: internal cardiac defibrillator; CRT: cardiac resynchronization therapy. Values are expressed as mean ± SD or (%). |